For age-old brands, it always seems more relevant to reaffirm an identity, establish legitimacy, build on history and continue to breathe new life into icons. At Cartier, this includes the launch of ...

As previously reported, BTIG initiated coverage of Tempus AI (TEM) with a Buy rating and $60 price target Tempus AI is a rapidly growing ...

Tempus AI (TEM) announced multi-year, strategic collaborations with AstraZeneca (AZN) and Pathos AI, Inc., in which the companies will work ...

CHICAGO, April 28, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop ...

Tempus AI, Inc. TEM is scheduled to report first-quarter fiscal 2025 results on May 6. In the last reported quarter, the company’s adjusted loss of 18 cents was wider than the Zacks Consensus ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology.

Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine with a market capitalization of $9.15 billion, announced the launch of Tempus Loop, a new platform designed to ...